Table 5 Blood lipid data of men (A) and women (B) before and following three weeks of supplementation with Ambrotose AO^® at a dosage of 4 capsules per day and placebo (cross-over design with a three week washout between conditions).

155.7 ± 9.7

149.0 ± 5.4

160.7 ± 12.1

159.9 ± 9.6

173.0 ± 13.6

169.8 ± 16.4

171.2 ± 13.6

173.6 ± 16.1

82.3 ± 11.6

93.6 ± 16.4

98.7 ± 17.7

95.3 ± 14.5

103.6 ± 31.6

80.2 ± 16.8

69.2 ± 10.6

94.0 ± 32.3

44.7 ± 2.9

45.1 ± 3.5

45.2 ± 3.0

47.0 ± 3.6

51.2 ± 6.1

53.0 ± 3.8

51.8 ± 4.0

46.2 ± 5.7

16.6 ± 2.3

18.6 ± 3.2

19.7 ± 3.5

19.1 ± 2.8

20.8 ± 6.4

16.0 ± 3.4

14.0 ± 2.0

18.8 ± 6.5

94.4 ± 8.5

85.3 ± 3.9

95.6 ± 9.8

93.7 ± 8.0

101.0 ± 13.2

100.8 ± 15.4

105.4 ± 13.7

108.6 ± 16.2

2.2 ± 0.3

2.0 ± 0.2

2.2 ± 0.3

2.1 ± 0.3

2.2 ± 0.6

2.0 ± 0.4

2.1 ± 0.5

2.7 ± 0.7

Trained Women Ambrotose AO ^® Pre

Trained Women Ambrotose AO ^® Post

Trained Women Placebo Pre

Trained Women Placebo Post

Untrained Women Ambrotose AO ^® Pre

Untrained Women Ambrotose AO ^® Post

Untrained Women Placebo Pre

Untrained Women Placebo Post

153.0 ± 5.8

146.7 ± 12.6

160.0 ± 14.2

154.7 ± 11.4

169.7 ± 9.4

167.7 ± 10.1

174.0 ± 6.4

175.3 ± 7.3

56.0 ± 6.9

52.1 ± 6.1

69.1 ± 11.2

66.3 ± 10.5

66.0 ± 8.6

70.3 ± 20.6

63.0 ± 11.4

71.5 ± 20.8

65.1 ± 4.3

63.1 ± 6.7

65.1 ± 7.6

61.7 ± 6.7

60.9 ± 3.5

62.8 ± 5.6

64.3 ± 6.1

69.2 ± 6.3

11.3 ± 1.4

10.4 ± 1.2

14.0 ± 2.3

13.3 ± 2.2

13.1 ± 1.8

14.0 ± 4.1

12.8 ± 2.3

14.2 ± 4.1

76.6 ± 5.5

73.1 ± 6.1

80.9 ± 6.9

79.7 ± 6.4

95.7 ± 9.0

90.8 ± 9.3

96.8 ± 7.9

92.0 ± 8.7

1.2 ± 0.1

1.2 ± 0.1

1.3 ± 0.1

1.3 ± 0.1

1.6 ± 0.1

1.5 ± 0.2

1.6 ± 0.2

1.4 ± 0.2